Cargando…
Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma
Inhibition of monocarboxylate transporter 1 has been proposed as a therapeutic approach to perturb lactate shuttling in tumor cells that lack monocarboxylate transporter 4. We examined the monocarboxylate transporter 1 inhibitor AZD3965, currently in phase I clinical studies, as a potential therapy...
Autores principales: | Noble, Richard A., Bell, Natalie, Blair, Helen, Sikka, Arti, Thomas, Huw, Phillips, Nicole, Nakjang, Sirintra, Miwa, Satomi, Crossland, Rachel, Rand, Vikki, Televantou, Despina, Long, Anna, Keun, Hector C., Bacon, Chris M., Bomken, Simon, Critchlow, Susan E., Wedge, Stephen R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566036/ https://www.ncbi.nlm.nih.gov/pubmed/28385782 http://dx.doi.org/10.3324/haematol.2016.163030 |
Ejemplares similares
-
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
por: Curtis, Nicola J., et al.
Publicado: (2017) -
In Vivo Anticancer Activity of AZD3965: A Systematic Review
por: Silva, Ana, et al.
Publicado: (2021) -
Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965
por: Braga, Marta, et al.
Publicado: (2020) -
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma
por: Newman, Alexander M., et al.
Publicado: (2021) -
A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965
por: McNeillis, Rosie, et al.
Publicado: (2020)